Autoantibodies against PLP1 likely contribute to CNS injury in a subset of MS patients, perhaps those presenting with type II white matter lesion pathology (1) and type III cortical demyelination, and operate at the earliest stages of disease. Here, PLP1 is linked to myeloid sarcoma.